Diffusion Pharmaceuticals (DFFN) Stock: Gaining Big On Patent News

Diffusion Pharmaceuticals Inc DFFN Stock News

Diffusion Pharmaceuticals Inc (NASDAQ: DFFN) is having an overwhelmingly strong start to the trading session today, and for good reason. The company announced patent news that led to excitement among investors, sending the stock screaming for the top. Today, we’ll talk about the news, what we’re seeing from the stock, and what we’ll be watching for with regard to DFFN ahead.

DFFN Announces Patent News

As mentioned above, Diffusion Pharmaceuticals is having an overwhelmingly strong start to the trading session this morning after announcing patent news. Early this morning the company issued a press release announcing the receipt of two patent application allowances. These patent application allowances relate to its lead compound known as trans sodium crocetinate, also known as TSC. According to the release, these patent allowances include claims for both method of use and composition of matter.

DFFN announced the first patent, NO. 14/933,047 includes claims relating to treating a number of cancers. These cancers include brain cancers like glioblastoma, as well as pancreas cancers. The claims cover the treatment of these cancers using bipolar trans cartenoids, including TSC, in combination with chemotherapy and radiation therapy. The second patent, NO. 14/642,703 includes claims relating to novel compositions of bipolar trans carotenoids, including TSC, for oral delivery. In a statement, David Kalergis, CEO at DFFN, had the following to offer:

We have worked hard to ensure our discoveries are protected and are grateful to receive these patent application allowances. We look forward to these patents being issued in the coming months… We believe strong intellectual property protections are vital to Diffusion’s ability to compete in the marketplace and to attract potential strategic partners. As we progress our pivotal Phase 3 study in inoperable glioblastoma patients who are administered TSC along with their standard therapies, we feel that it is imperative that our proprietary position be protected to add increased value to the Company. 

Stop wasting your time! Start finding winning trades in minutes with Trade Ideas!

Leave a Comment